SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
Active, not recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT05408936
- Lead Sponsor
- University of Patras
- Brief Summary
Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function.
The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit.
A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- type 2 diabetes
- Hba1C>7% on their current treatment
- introduction of SGLT2 inhibitor as part of their routine care
Exclusion Criteria
- eGFR<60 ml/min
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Erythropoetin 0-1-3 months NT-proBNP 0-1-3 months Hemoglobin 0-1-3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital of Patras
🇬🇷Patras, Greece